Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients

This study has been completed.
Sponsor:
Collaborator:
Beckman Laser Institute University of California Irvine
Information provided by (Responsible Party):
Beckman Laser Institute and Medical Center, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00581295
First received: December 19, 2007
Last updated: August 5, 2015
Last verified: August 2015

December 19, 2007
August 5, 2015
March 2007
April 2011   (final data collection date for primary outcome measure)
The ability to noninvasively diagnose conditions in the intensive care unit, or in battlefield conditions. [ Time Frame: 5 to 60 seconds ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00581295 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients
Use of Diffuse Optical Spectroscopy for Evaluation of the Trauma/Critically Care Patients

Trauma remains the leading cause of death and disability for Americans age 1-44. Trauma can cause internal bleeding, and this bleeding is often hard to detect without sophisticate tests that take time to complete and analyze.

In addition, internal bleeding, including bleeding into the lung and chest cavity, as well as other blood loss, happens in many critically ill patients. For example, for hemorrhage, it is very difficult to detect active hemorrhage and to determine optimal rates of fluid and blood resuscitation.

Diffuse optical spectroscopy has the potential to accurately assess adequacy of tissue perfusion, oxygenation, tissue oxygen extraction, and cytochrome oxidation states that may be critical to optimal treatment, end- organ preservation, and survival.

The research' want to monitor tissue perfusion and indicators of tissue damage and viability in critically ill patients by using DOS.

Non-invasive Optical Techniques DOS,near-infrared diffuse optical spectroscopy (NIR-DOS.

NIR-DOS provides functional physiologic tissue/organ information without ionizing radiation and without withdrawing any blood, in a cost-effective and rapid manner. The application of frequency-domain photon migration analysis (FDPM) to NIRS allows independent measurements of tissue absorption and scattering properties at depths of 1 cm or more below the skin surface.

Such capabilities will improve early diagnosis, detection, optimization of therapy, assessment of adequacy of resuscitation, and alteration in management plans for all of these critical conditions.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Trauma/Critically Care Patients
Trauma
Device: Diffuse optical spectroscopy
Diffuse optical spectroscopy measurment
trauma
Diffuse optical spectroscopy measurment
Intervention: Device: Diffuse optical spectroscopy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
93
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult age 18 years or older, male or female
  • Trauma/Critical Care patient

Exclusion Criteria:

  • Subject is not Trauma/Critical Care patient
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00581295
NIH-LAMMP-2013-9435
No
Not Provided
Not Provided
Beckman Laser Institute and Medical Center, University of California, Irvine
University of California, Irvine
Beckman Laser Institute University of California Irvine
Principal Investigator: Michael E Lekawa, M.D Beckman Laser Institute
University of California, Irvine
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP